miR-92a-3p regulates cisplatin-induced cancer cell death

Abstract

Non-small cell lung cancer is characterized by a dismal prognosis largely owing to inefficient diagnosis and tenacious drug resistance. Therefore, the identification of new molecular determinants underlying sensitivity of cancer cells to existing therapy is of particular importance to develop new effective combinatorial treatment strategy. MicroRNAs (miRNAs), a class of small non-coding RNAs, have been established as master regulators of a variety of cellular processes that play a key role in tumor initiation, progression and metastasis. This, along with their widespread deregulation in many distinct cancers, has triggered enthusiasm for miRNAs as novel therapeutic targets for cancer management, in particular in patients with refractory cancers such as those harboring KRAS mutations. In this study, we performed a loss-of-function screening approach to identify miRNAs whose silencing promotes sensitivity of lung adenocarcinoma (LUAD) cells to cisplatin. Our results showed in particular that antisense oligonucleotides directed against miR-92a-3p, a member of the oncogenic miR-17 ~ 92 cluster, caused the greatest increase in the sensitivity of KRAS-mutated LUAD cells to cisplatin. In addition, we demonstrated that this miRNA finely regulates the apoptotic threshold and the proliferative capacity of various tumor cell lines with distinct genetic alterations. Collectively, these data suggest that targeting miR-92a-3p may serve as an effective strategy to overcome treatment resistance of solid tumors.

Erianin promotes apoptosis and inhibits Akt-mediated aerobic glycolysis of cancer cells

“…Lung cancer is the most common cause of cancer-related deaths worldwide, among which non-small cell lung cancer (NSCLC) accounts for 80%-85% [1][2][3][4]. Over the past decade, the treatment paradigm for NSCLC has progressed dramatically including chemotherapeutic agents, molecularly targeted drugs, and immune checkpoints inhibitors [5][6][7][8][9][10][11][12]. However, the vast majority of advanced NSCLC become resistant to current treatments and eventually progress [1,13,14].…”